Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elafibranor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 8/20 | 1.00 |
| ▸ | PPARD known ✓ | Q03181 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elafibranor SCHEMBL23143340 | 1.00 | PPARA (1.00) | PPARAPPARDPPARGKCNH2MEN1 | |
| Elafibranor SCHEMBL16552997 | 1.00 | PPARA (1.00) | PPARAPPARDPPARGKCNH2MEN1 | |
| SCHEMBL20710988 | 0.91 | PPARA (0.84) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL21351480 | 0.91 | PPARA (0.83) | PPARAPPARDPPARGMEN1ALDH1A1 | |
| SCHEMBL20110591 | 0.91 | PPARA (0.83) | PPARAPPARDPPARGMEN1ALDH1A1 | |
| SCHEMBL20932824 | 0.89 | PPARG (0.80) | PPARAPPARDPPARGMEN1ALDH1A1 | |
| SCHEMBL20032087 | 0.89 | PPARG (0.80) | PPARAPPARDPPARGMEN1ALDH1A1 | |
| SCHEMBL13359231 | 0.88 | PPARA (0.78) | PPARAPPARDPPARGKCNH2MAPT | |
| SCHEMBL13764693 | 0.88 | PPARA (0.78) | PPARAPPARDPPARGKCNH2 | |
| SCHEMBL814753 | 0.88 | PPARA (0.78) | PPARAPPARDPPARGMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2308 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| US-12589086-B2 | Compositions and methods for the treatment of primary biliary cholangitis | GENFIT (FR) | 2026-03-31 | — | — | US | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| US-20260027075-A1 | SOLID DOSAGE FORMS OF ELAFIBRANOR | GENFIT (FR) | 2026-01-29 | — | — | US | claimed |
| EP-4677084-A1 | MODIFIED SHORT INERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12522564-B2 | Polymorphs of elafibranor | GENFIT (FR) | 2026-01-13 | — | — | US | claimed |
| WO-2021055725-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2021-03-25 | — | — | WO | claimed |
| EP-3777863-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2020163240-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | claimed |
| WO-2020039297-A1 | NOVEL COMPOUNDS AND THEIR USE IN PREPARATION OF ELAFIBRANOR AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | MANKIND PHARMA LTD. (IN) | 2020-02-27 | — | — | WO | claimed |
| US-20180296562-A1 | USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB | TRANSTECH PHARMA, LLC | 2018-10-18 | — | — | US | claimed |
| US-20180008616-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | claimed |
| US-20170319548-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | US | claimed |
| EP-3191100-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016127019-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. (US) | 2016-08-11 | — | — | WO | claimed |
| WO-2016040860-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |